"Phase IB trial of carboxyamidotriazole orotate (CTO) and temozolomide for recurrent malignant glioma (MG): A novel mechanism for modulation of multiple oncogenic pathways." by Antonio Marcilio Padula Omuro

Selected Works of Walter J. Urba, MD, PhD

Article

Phase IB trial of carboxyamidotriazole orotate (CTO) and temozolomide for recurrent malignant glioma (MG): A novel mechanism for modulation of multiple oncogenic pathways.

Journal of Clinical Oncology (2017)

Antonio Marcilio Padula Omuro, Memorial Sloan Kettering Cancer Center
Thomas Joseph Kaley, Memorial Sloan Kettering Cancer Center
Elena Pentsova, Memorial Sloan Kettering Cancer Center
Lisa Marie DeAngelis, Memorial Sloan Kettering Cancer Center
Walter John Urba
Matthew Hiram Taylor, Oregon Health & Science University
Barry Douglas Anderson, National Institutes of Health
Greg Gorman, University of Birmingham
Sean McLean, Princeton University
Rashida A. Karmali, Duke University

Disciplines

Publication Date

January 31, 2017

Citation Information

Antonio Marcilio Padula Omuro, Thomas Joseph Kaley, Elena Pentsova, Lisa Marie DeAngelis, et al.. "Phase IB trial of carboxyamidotriazole orotate (CTO) and temozolomide for recurrent malignant glioma (MG): A novel mechanism for modulation of multiple oncogenic pathways." Journal of Clinical Oncology (2017)
Available at: http://works.bepress.com/walter-urba/96/